Table S6 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
<p>Glioblastoma patient characteristics (DFCI)</p>
Na minha lista:
| Autor principal: | Joseph Toker (15399882) (author) |
|---|---|
| Outros Autores: | J. Bryan Iorgulescu (15030477) (author), Alexander L. Ling (15399885) (author), Genaro R. Villa (15399888) (author), Josephina A.M.A. Gadet (15399891) (author), Laxmi Parida (15112564) (author), Gad Getz (14945542) (author), Catherine J. Wu (14944480) (author), David A. Reardon (15043854) (author), E. Antonio Chiocca (15399894) (author), Marco Mineo (15399897) (author) |
| Publicado em: |
2025
|
| Assuntos: | |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|
Registos relacionados
-
Table S2 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
Por: Joseph Toker (15399882)
Publicado em: (2025) -
Table S3 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
Por: Joseph Toker (15399882)
Publicado em: (2025) -
Table S4 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
Por: Joseph Toker (15399882)
Publicado em: (2025) -
Table S5 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
Por: Joseph Toker (15399882)
Publicado em: (2025) -
Table S7 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
Por: Joseph Toker (15399882)
Publicado em: (2025)